Results 101 to 110 of about 106,545 (283)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Proteomes, 2014
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases.
Katerina Arvaniti, Anastasia Papadioti, Maria Kinigopoulou, Vassiliki Theodorou, Konstantinos Skobridis, Georgios Tsiotis   +5 more
doaj   +1 more source

Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]

, 2005
Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR, DEL GIUDICE, ILARIA, DIVERIO D, FOA, Roberto, GIONA, Fiorina, MANDELLI, Franco, MOLETI ML, TESTI, Anna Maria   +7 more
core   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, EarlyView.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

Structural Basis for the Regulation of PPARγ Activity by Imatinib

Molecules, 2019
Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor γ (PPARγ) phosphorylation at Ser245 to evaluate
Jun Young Jang, Hyun-Jung Kim, Byung Woo Han   +2 more
doaj   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

Imatinib: Paradigm or Anomaly? [PDF]

Cell Cycle, 2004
The introduction of imatinib (Gleevec, Glivec, formerly STI571), an agent targeting the causative molecular event in chronic myeloid leukemia (CML) has been heralded as a major advance in the treatment of cancer. Certainly, the clinical trials with imatinib have validated the concept that a precise understanding of the pathogenesis of a cancer can lead
openaire   +3 more sources

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +1 more source

Pharmacists' views on the implementation of therapeutic drug monitoring in oncology

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background There is increasing interest in the potential benefit of therapeutic drug monitoring (TDM) in oncology. However, uptake in Australian hospitals is limited. Aim This study sought to explore hospital pharmacists' experiences with TDM in oncology, seeking to determine if they could provide insights into barriers and facilitators to its
Jane E. Carland, Bridin Murnion, Thomas Sakellaris, Jana Stojanova   +3 more
wiley   +1 more source

Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China

Therapeutic Advances in Hematology
Background: Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib.
Fang Cheng, Di Wu, Zheng Cui, Qiang Li, Weiming Li, Yu Zhang   +5 more
doaj   +1 more source